KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deferred Tax Liability (2020 - 2025)

Historic Non-Current Deferred Tax Liability for Castle Biosciences (CSTL) over the last 6 years, with Q3 2025 value amounting to $3.2 million.

  • Castle Biosciences' Non-Current Deferred Tax Liability fell 2317.54% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 2317.54%. This contributed to the annual value of $1.6 million for FY2024, which is 9348.79% down from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Non-Current Deferred Tax Liability is $3.2 million, which was down 2317.54% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Non-Current Deferred Tax Liability registered a high of $27.1 million during Q4 2022, and its lowest value of $206000.0 during Q1 2024.
  • For the 5-year period, Castle Biosciences' Non-Current Deferred Tax Liability averaged around $5.9 million, with its median value being $837000.0 (2025).
  • Examining YoY changes over the last 5 years, Castle Biosciences' Non-Current Deferred Tax Liability showed a top increase of 85691.61% in 2024 and a maximum decrease of 9348.79% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Non-Current Deferred Tax Liability stood at $19.6 million in 2021, then soared by 38.56% to $27.1 million in 2022, then decreased by 9.0% to $24.7 million in 2023, then crashed by 93.49% to $1.6 million in 2024, then soared by 101.74% to $3.2 million in 2025.
  • Its Non-Current Deferred Tax Liability was $3.2 million in Q3 2025, compared to $3.1 million in Q2 2025 and $837000.0 in Q1 2025.